指南与共识临床试验与 GCP真实世界研究与卫生经济

急性髓系白血病未来临床试验的核心结局集测量:HARMONY研究方案

Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting.
指南 / 共识 · Trials · 2020-05-27

HARMONY联盟拟通过三轮Delphi调查和最终共识会议,为急性髓系白血病(AML)临床试验制定核心结局集。参与者来自患者、临床医生、监管机构及制药行业协会等多利益相关方,前期经文献检索和访谈形成初步结局清单,Delphi调查筛选核心结局,最终面对面会议达成共识。该核心结局集有望促进未来临床试验和真实世界证据研究的一致比较。

要点

  • AML临床试验结局不统一导致试验间难以直接比较,亟需核心结局集。
  • 采用三轮Delphi调查和最终共识会议,多利益相关方参与制定核心结局集。
  • 核心结局集将助力未来临床试验和真实世界证据研究的一致比较。

核心结论

  • HARMONY联盟的试点Delphi研究旨在基于多利益相关方共识为AML定义核心结局集。

研究设计与样本

  • 采用三轮Delphi调查和一次最终共识会议,参与者来自患者、临床医生、监管机构及制药行业协会等多利益相关方。
  • 预Delphi阶段进行文献检索、半结构化访谈和多利益相关方面对面会议,形成初步结局清单。

临床怎么用

  • 核心结局集可用于指导未来AML临床试验的结局选择与 harmonization,并支持真实世界证据研究的一致比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute myeloid leukemia (AML) is the most common acute leukemia in adults and has an unacceptably low cure rate. In recent years, a number of new treatment strategies and compounds were developed for the treatment of AML. There were several randomized controlled clinical trials with the objective to improve patients' management and patients' outcome in AML. Unfortunately, these trials are not always directly comparable since they do not measure the same outcomes, and currently there are no core outcome sets that can be used to guide outcome selection and harmonization in this disease area. The HARMONY (Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology) Alliance is a public-private European network established in 2017 and currently includes 53 partners and 32 associated members from 22 countries. Amongst many other goals of the HARMONY Alliance, Work Package 2 focuses on defining outcomes that are relevant to each hematological malignancy. Accordingly, this pilot study will be performed to define a core outcome set in AML. METHODS: The pilot study will use a three-round Delphi survey and a final consensus meeting to define a core outcome set. Participants will be recruited from different stakeholder groups, including patients, clinicians, regulators and members of the European Federation of Pharmaceutical Industries and Associations. At the pre-Delphi stage, a literature research was conducted followed by several semi-structured interviews of clinical public and private key opinion leaders. Subsequently, the preliminary outcome list was discussed in several multi-stakeholder face-to-face meetings. The Delphi survey will reduce the preliminary outcome list to essential core outcomes. After completion of the last Delphi round, a final face-to-face meeting is planned to achieve consensus about the core outcome set in AML. DISCUSSION: As part of the HARMONY Alliance, the pilot Delphi aims to define a core outcome set in AML on the basis of a multi-stakeholder consensus. Such a core outcome set will help to allow consistent comparison of future clinical trials and real-world evidence research and ensures that appropriate outcomes valued by a range of stakeholders are measured within future trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lang KM, Harrison KL, Williamson PR, et al. Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. Trials. 2020. PMID: 32460828. doi:10.1186/s13063-020-04384-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。